Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences Regulation of Dietary Supplements and Other Specialized Categories Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157 ORAL Beverly Hills Rejuvenation Center FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare